Table of Contents
A prior art search Strasbourg litigation team can rely on has to reflect where the disputes come from — and in Strasbourg they come from chemistry. The city sits in Alsace on the German border, in BioValley, the trinational Upper Rhine life-science corridor. Eli Lilly’s Fegersheim plant, University of Strasbourg and CNRS chemistry, and the IGBMC genetics institute make pharma, biotech and chemistry patents the local litigation theme. Yet a Strasbourg dispute is not tried in Strasbourg: France gives the Paris Judicial Court exclusive national jurisdiction over infringement and validity. PerspireIP builds invalidity-grade searches for the accused parties and counsel fighting those patents across France, the EPO and the Unified Patent Court.
Where a prior art search Strasbourg case is actually heard
France concentrates all patent litigation in a single forum. The Paris Judicial Court (Tribunal judiciaire de Paris) has exclusive national jurisdiction over patent infringement and over nullity (invalidity) actions, and appeals go to the Paris Court of Appeal (Cour d’appel de Paris). A dispute rooted in Strasbourg — over an Alsace pharma process or an Upper Rhine chemistry patent — is still filed and tried in Paris. There is no patent venue in Grand Est.
That single-court design makes the prior art decisive. In a French nullity action the accused party asks the Paris court to revoke the patent for lack of novelty or inventive step, and the outcome turns on what was publicly available before the priority date. Whether the fight is a defensive counterclaim or a standalone nullity action, the invalidity search is the engine of the case.
- Tribunal judiciaire de Paris — exclusive first-instance court for French infringement and nullity
- Cour d’appel de Paris — hears all patent appeals, including INPI opposition appeals
- EPO Opposition Division — central attack on a European patent within nine months of grant
- Unified Patent Court — revocation of unitary and non-opted-out European patents, seat in Paris
BioValley and the Upper Rhine: where Strasbourg’s patent fights come from
Strasbourg anchors the French wing of BioValley, the trinational life-science cluster founded in 1996 across the Upper Rhine in France, Germany and Switzerland. An estimated 32,000 people work in life sciences across the region, alongside hundreds of pharma, biotech and medtech companies. Eli Lilly’s Fegersheim site near Strasbourg — one of the world’s main insulin-pen and injectable plants, operating since 1967 — sits at the centre of this corridor.
The research base is just as concentrated. The University of Strasbourg and CNRS have deep roots in chemistry, and the IGBMC (Institute of Genetics and of Molecular and Cellular Biology) is a leading genetics centre. Companies such as Transgene and NovAliX add biotech and drug-discovery depth. The result: local patent disputes cluster around small molecules, formulations, biologics, sequences and chemical processes — not consumer tech.
Where pharma, biotech and chemistry prior art lives
Chemistry and life-science patents are anticipated in a different literature than electronics or software. A great deal of the decisive art never appears in a patent database at all — it lives in the journal record and in specialist compound and sequence collections. A credible invalidity search in this field has to reach those sources and prove the public-availability date of each one.
- Chemical Abstracts (CAS) and the peer-reviewed journal literature, where a synthesis or compound may first be disclosed
- Sequence and structure databases for biologics, peptides and nucleic-acid claims
- Older patent families, often argued as inventive-step (obviousness) combinations under EPO problem-and-solution
- Conference abstracts, theses and dated technical disclosures that predate the priority date
For a formulation or process claim the anticipating reference is frequently an older paper or an abandoned patent family, not the headline blockbuster. We treat dating as evidence to be proved — establishing that each reference was genuinely public before the priority date the claim actually relies on.
French nullity, EPO opposition or UPC revocation: three routes
An accused party in Strasbourg usually has more than one way to attack a patent, and they are not interchangeable. A French nullity action runs before the Paris Judicial Court and revokes the French designation. EPO opposition is a central attack: filed within nine months of grant, it can knock out the European patent in every designated state at once, decided on novelty and inventive step.
The Unified Patent Court adds a third route. Its Central Division has its seat in Paris; a UPC revocation action can kill a unitary patent, or a European patent that has not been opted out, across all participating states in one judgment. Chemistry validity is handled by the Munich section and healthcare by Milan, while supplementary protection certificate validity stays in Paris — allocation that matters for Alsace pharma.
The routes share one dependency: prior art. One rigorous invalidity search, charted claim by claim, can feed a Paris nullity counterclaim, an EPO opposition and a UPC revocation at the same time, so the same evidence works across every forum.
Cross-border enforcement across the Upper Rhine
Strasbourg’s defining feature is the German border. Products, research and supply chains routinely cross between Alsace, Baden-Württemberg and Basel, so the same patent family is often asserted on both sides of the Rhine. A patent enforced in France may have German siblings enforced before the German courts or the UPC’s German local divisions, and a Swiss dimension through Basel’s pharma majors.
That cross-border reality changes how a prior art search Strasbourg counsel commissions should be scoped. The art has to be robust across jurisdictions and languages — French, German and English — because a reference that anticipates a claim in Paris should also carry weight in an EPO opposition or a parallel German proceeding. We build searches that travel, so one evidence set supports coordinated defence across the whole Upper Rhine.
No patent court in Strasbourg — and why it doesn’t matter
Strasbourg is famous as a seat of European institutions — the European Parliament, the Council of Europe and the European Court of Human Rights all sit here. None of them hears patent cases. Patent venue in France is a separate, specialised system: infringement and validity go to the Paris Judicial Court, European patents are opposed at the EPO in Munich, and unitary patents are revoked at the UPC. Proximity to Strasbourg’s institutions confers no patent forum.
Registration is equally national. The INPI (Institut national de la propriété industrielle) grants French patents and, since 2020, hears INPI opposition, with appeals to the Paris Court of Appeal. But none of this decides a validity fight. What decides it is the strength and dating of the prior art — a CAS-indexed synthesis, an older patent family, a sequence disclosure — not a local address.
How PerspireIP builds a prior art search Strasbourg case can rely on
Every engagement follows the same disciplined path. We map the asserted claims element by element, fix the priority date that actually governs each one, and search against that date rather than the filing date on the cover. For pharma, biotech and chemistry subject-matter we run patent and deep non-patent-literature searching in parallel — CAS, journals, sequence and structure databases — then build claim charts a Paris judge, an EPO Opposition Division or a UPC panel can follow.
- Claim charting mapped to novelty and inventive step under the EPC and French law
- Deep retrieval across CAS, peer-reviewed journals, sequence databases and older patent families
- Public-availability dating for every reference, evidenced in French, German and English
- Prior art sized to your forum — a Paris nullity action, the nine-month EPO opposition window, or UPC revocation
- A written invalidity analysis and reference packages ready for court, the EPO or the UPC
We work alongside your French and European counsel as a specialist search partner, deliver to Paris, EPO and UPC deadlines, and keep every engagement confidential. Whether you are an Alsace manufacturer facing an assertion, a generics or biosimilar entrant clearing a path, or litigation counsel preparing a cross-border defence, we scale to fit — a single search, a multi-patent campaign or ongoing support. Send us the patent number and your key dates, and we will scope a prior art search Strasbourg project within one business day.
IP Landscape & Resources in Strasbourg
Key intellectual-property authorities and venues relevant to Strasbourg:
- INPI (Institut national de la propriété industrielle) — the French patent office; grants French patents and hears INPI opposition, with appeals to the Paris Court of Appeal
- Tribunal judiciaire de Paris — the Paris Judicial Court with exclusive national jurisdiction over French patent infringement and nullity actions
- European Patent Office (EPO) — grants European patents and runs post-grant opposition, a central attack filed within nine months of grant
- Unified Patent Court (UPC) — hears revocation of unitary and non-opted-out European patents; its Central Division seat is in Paris
Request a Prior Art Search in Strasbourg
Request a Prior Art Search in Strasbourg
Get an invalidity-grade prior-art search built for a Paris nullity action, a nine-month EPO opposition, or UPC revocation, tuned for pharma, biotech and Upper Rhine chemistry claims. Send us the patent number and your key dates, and we will scope the work within one business day.
Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.
Frequently Asked Questions
Why is a Strasbourg patent case litigated in Paris?
Because French law gives the Paris Judicial Court (Tribunal judiciaire de Paris) exclusive national jurisdiction over patent infringement and nullity actions, with appeals to the Paris Court of Appeal. There is no patent venue in Strasbourg or Grand Est, so a dispute arising from an Alsace or Upper Rhine patent is still filed and tried in Paris. Strasbourg’s European institutions do not hear patent cases; venue is a separate, specialised national system.
French nullity, EPO opposition or UPC revocation — which route invalidates the patent?
They do different things. A French nullity action before the Paris court revokes only the French designation. EPO opposition, filed within nine months of grant, is a central attack that can revoke the European patent in all designated states at once. UPC revocation kills a unitary patent, or a non-opted-out European patent, across participating states in one judgment; its Central Division seat is in Paris, with chemistry validity in Munich and healthcare in Milan. One prior art search can feed all three.
Where does pharma, biotech and chemistry prior art actually live?
Often outside patent databases. The decisive art for a chemistry or life-science claim frequently sits in the journal literature indexed by Chemical Abstracts (CAS), in sequence and structure databases for biologics and nucleic-acid claims, and in older or abandoned patent families argued as inventive-step combinations. Conference abstracts and theses matter too. We search those sources directly and prove each reference was public before the claim’s priority date.
Can one search support cross-border enforcement across the Upper Rhine?
Yes, and it usually should. Strasbourg sits on the German border in the trinational BioValley corridor, so the same patent family is often asserted in France, Germany and Switzerland at once. We build invalidity evidence that travels across jurisdictions and languages — French, German and English — so a reference that works in a Paris nullity action also carries weight in an EPO opposition or a parallel German or UPC proceeding, supporting a coordinated cross-border defence.